MediciNova's Q3 Loss Widens Amid Increased R&D Spend

TL;DR

**MNOV is burning cash faster than it's making it, and without a major clinical win or capital raise, this stock is a risky bet.**

AI Summary

MediciNova, Inc. (MNOV) reported a net loss of $3,050,373 for the three months ended September 30, 2025, an increase from a net loss of $2,852,179 for the same period in 2024, representing a 7% increase in loss. For the nine months ended September 30, 2025, the net loss widened to $9,195,678 from $8,234,897 in 2024, an 11.7% increase. The company generated revenues of $123,319 for the three months and $257,918 for the nine months ended September 30, 2025, compared to zero revenue in the prior year periods, indicating the initiation of revenue-generating activities. Operating expenses increased to $3,504,317 for the quarter and $10,448,518 for the nine months in 2025, up from $3,309,128 and $9,491,617 respectively in 2024. Cash and cash equivalents decreased significantly to $32,562,612 as of September 30, 2025, from $40,359,738 at December 31, 2024, a 19.3% decline. The company continues to focus on developing MN-166 (ibudilast) and MN-001 (tipelukast) for various serious diseases, and expects to incur further losses, requiring additional capital for clinical trial programs.

Why It Matters

MediciNova's continued net losses and declining cash reserves are critical for investors, signaling ongoing capital requirements to fund its MN-166 and MN-001 clinical programs. The emergence of revenue, albeit small at $257,918, is a new development but insufficient to offset rising operating costs, particularly in research and development. For employees, the company's long-term viability hinges on successful clinical trials and securing additional funding. Customers and the broader market await potential breakthroughs from its drug candidates, but the competitive biopharmaceutical landscape means MNOV must demonstrate significant efficacy to gain market share and investor confidence.

Risk Assessment

Risk Level: high — MediciNova has incurred net losses since its inception and has negative operating cash flows, with a net loss of $9,195,678 for the nine months ended September 30, 2025. Cash and cash equivalents decreased by 19.3% from $40,359,738 at December 31, 2024, to $32,562,612 at September 30, 2025, indicating a significant cash burn rate. The company explicitly states it expects to continue incurring losses and will require additional capital, posing a substantial liquidity risk.

Analyst Insight

Investors should exercise extreme caution and consider the high risk associated with MNOV. Given the consistent net losses and declining cash position, potential investors should await clear evidence of successful clinical trial outcomes for MN-166 or MN-001 and a concrete plan for securing additional capital before considering an investment.

Financial Highlights

debt To Equity

N/A

revenue

$257,918

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$9,195,678

eps

N/A

gross Margin

N/A

cash Position

$32,562,612

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $3,050,373 — Net loss for Q3 2025 (Increased from $2,852,179 in Q3 2024)
• $9,195,678 — Net loss for nine months ended Sept 30, 2025 (Increased from $8,234,897 in the prior year period)
• $32,562,612 — Cash and cash equivalents as of Sept 30, 2025 (Decreased from $40,359,738 at Dec 31, 2024)
• $257,918 — Revenues for nine months ended Sept 30, 2025 (Compared to $0 in the prior year period)
• $10,448,518 — Total operating expenses for nine months ended Sept 30, 2025 (Increased from $9,491,617 in the prior year period)
• 49,046,246 — Shares of Common Stock outstanding (As of November 10, 2025)
• $1,582,975 — Research, development and patents expense for Q3 2025 (Decreased from $1,859,400 in Q3 2024)
• $5,611,429 — Research, development and patents expense for nine months ended Sept 30, 2025 (Increased from $5,287,318 in the prior year period)

Key Players & Entities

• MediciNova, Inc. (company) — registrant
• MN-166 (ibudilast) (company) — product candidate for neurological and other disorders
• MN-001 (tipelukast) (company) — product candidate for fibrotic and other metabolic disorders
• Nasdaq Global Market (regulator) — stock exchange where common stock is listed
• Tokyo Stock Exchange (regulator) — stock exchange where common stock is listed
• SEC (regulator) — Securities and Exchange Commission
• Chief Executive Officer (person) — member of the Chief Operating Decision-Maker committee
• Chief Medical Officer (person) — member of the Chief Operating Decision-Maker committee
• Chief Financial Officer (person) — member of the Chief Operating Decision-Maker committee
• Delaware (regulator) — state of incorporation

FAQ

Risk Factors

• Continued Net Losses and Need for Capital [high — financial]: The company reported a net loss of $3,050,373 for Q3 2025 and $9,195,678 for the nine months ended September 30, 2025. MediciNova expects to incur further losses and requires additional capital to fund its clinical trial programs, posing a significant financial risk.
• Drug Development and Approval Risks [high — regulatory]: MediciNova's success is heavily dependent on the successful development and regulatory approval of its drug candidates, MN-166 (ibudilast) and MN-001 (tipelukast). Delays or failures in clinical trials or regulatory reviews can severely impact the company's prospects.
• Dependence on Key Personnel and Research [medium — operational]: The company's ability to advance its drug pipeline relies on its research and development team and its ability to secure intellectual property. Any disruption in these areas could hinder progress.
• Competition in Therapeutic Areas [medium — market]: MediciNova operates in competitive therapeutic areas. The success of its drug candidates will be measured against existing treatments and other pipeline drugs from competitors.
• Declining Cash Reserves [high — financial]: Cash and cash equivalents decreased by 19.3% from $40,359,738 at December 31, 2024, to $32,562,612 as of September 30, 2025. This decline, coupled with ongoing losses, highlights the need for careful cash management and future fundraising.

Industry Context

MediciNova operates in the biopharmaceutical industry, focusing on the development of novel therapeutics for serious diseases. This sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success is often driven by innovation in drug discovery and successful clinical trial outcomes.

Regulatory Implications

The company's drug candidates, MN-166 and MN-001, are subject to rigorous review by regulatory bodies like the FDA. Any delays or adverse findings in clinical trials or manufacturing processes could lead to significant setbacks and impact market entry.

What Investors Should Do

1. Monitor cash burn rate and future financing needs.
2. Track progress of MN-166 and MN-001 clinical trials.
3. Evaluate the sustainability of revenue generation.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $3,050,373 and generated $123,319 in revenue, with cash and cash equivalents at $32,562,612.
• 2025-09-30: Nine months ended September 30, 2025 — Accumulated net loss of $9,195,678 and generated $257,918 in revenue.
• 2024-12-31: End of Fiscal Year 2024 — Cash and cash equivalents were $40,359,738, serving as a baseline for the current period's decline.

Glossary

MN-166 (ibudilast)

A drug candidate developed by MediciNova for various serious diseases. (Central to the company's product pipeline and future revenue potential.)

MN-001 (tipelukast)

Another drug candidate in development by MediciNova. (Part of the company's research and development efforts, contributing to potential future value.)

Net loss

The amount by which total expenses exceed total revenues over a specific period. (Indicates the company's current profitability status, which is negative and increasing.)

Cash and cash equivalents

Highly liquid investments that are readily convertible to known amounts of cash and which are so near their maturity that they present an insignificant risk of changes in value. (Represents the company's immediate liquidity and ability to fund operations and clinical trials.)

Year-Over-Year Comparison

Compared to the prior year, MediciNova has begun generating revenue, with $257,918 reported for the nine months ended September 30, 2025, versus zero in the prior period. However, net losses have also widened, increasing by 11.7% for the nine-month period to $9,195,678. Operating expenses have risen, and cash reserves have seen a significant decline of 19.3% from the end of the previous fiscal year, indicating increased investment in operations and development alongside early commercialization efforts.

Key Financial Figures

• $0.001 — ction 12(b) of the Act: Common Stock, $0.001 par value MNOV The Nasdaq Stock Mar

Filing Documents

• mnov-20250930.htm (10-Q) — 1346KB
• mnov-ex31_1.htm (EX-31.1) — 16KB
• mnov-ex31_2.htm (EX-31.2) — 16KB
• mnov-ex32_1.htm (EX-32.1) — 11KB
• mnov-ex32_2.htm (EX-32.2) — 12KB
• 0001193125-25-277779.txt ( ) — 5572KB
• mnov-20250930.xsd (EX-101.SCH) — 711KB
• mnov-20250930_htm.xml (XML) — 992KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 5 ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) 5 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 17 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 22 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 22

OTHER INFORMATION

PART II. OTHER INFORMATION 23 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 23 ITEM 1A.

RISK FACTORS

RISK FACTORS 23 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 23 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 23 ITEM 4. MINE SAFETY DISCLOSURES 23 ITEM 5. OTHER INFORMATION 23 ITEM 6. EXHIBITS 24

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

CONDENSED CONSOLIDATED F INANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLIDATED F INANCIAL STATEMENTS. MEDICINOVA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 32,562,612 $ 40,359,738 Prepaid expenses and other current assets 359,909 714,541 Total current assets 32,922,521 41,074,279 Goodwill 9,600,240 9,600,240 In-process research and development 4,800,000 4,800,000 Property and equipment, net 12,933 25,507 Right-of-use asset 223,698 356,904 Other non-current assets 18,996 18,996 Total assets $ 47,578,388 $ 55,875,926 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 745,958 $ 1,102,494 Accrued liabilities and other current liabilities 1,888,833 1,662,860 Deferred revenue 521,899 — Operating lease liability 180,751 193,769 Total current liabilities 3,337,441 2,959,123 Deferred tax liability 201,792 201,792 Other non-current liabilities 74,399 211,460 Total liabilities 3,613,632 3,372,375 Commitments and contingencies (Note 4) Stockholders' equity: Common stock, $ 0.001 par value; 100,000,000 shares authorized at September 30, 2025 and December 31, 2024; 49,046,246 and 49,046,246 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 49,046 49,046 Additional paid-in capital 479,989,433 479,340,901 Accumulated other comprehensive loss ( 126,803 ) ( 135,154 ) Accumulated deficit ( 435,946,920 ) ( 426,751,242 ) Total stockholders' equity 43,964,756 52,503,551 Total liabilities and stockholders' equity $ 47,578,388 $ 55,875,926 See accompanying notes. 5 MEDICINOVA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Three months ended Nine months ended September 30, September 30, 2025 2024 2025 2024 Revenues $ 1

View Full Filing

View this 10-Q filing on SEC EDGAR